Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients

Arthritis and Rheumatism

Volumn 56, Issue 10, 2007, Pages 3442-3447

  Manetti, Mirko ^a,b,c   Neumann, Elena ^b,c   Milia, Anna Franca ^a   Tarner, Ingo H ^b,c   Bechi, Paolo ^a   Matucci Cerinic, Marco ^a   Ibba Manneschi, Lidia ^a   Müller Ladner, Ulf ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; ENDOTHELIN 1; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; FIBROGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH BIOPSY; STOMACH MOTILITY; STOMACH MUSCLE; STOMACH WALL; SYSTEMIC SCLEROSIS;

ACTINS; AGED; BIOPSY; CASE-CONTROL STUDIES; COLLAGEN TYPE I; COLLAGEN TYPE III; COLLAGEN TYPE IV; CYTOKINES; ENDOTHELIN-1; FEMALE; FIBROSIS; GASTROSCOPY; GENE EXPRESSION; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; STOMACH; TRANSFORMING GROWTH FACTOR BETA;

EID: 35348891007     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22940     Document Type: Article

References (13)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
3. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
4. Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
5. Lock G, Holtstege A, Lang B, Scholmerich J. Gastrointestinal manifestation of progressive systemic sclerosis. Am J Gastroenterol 1997;92:763-71.
6. Sjogren RW. Gastrointestinal motility disorders in scleroderma [review]. Arthritis Rheum 1994;37:1265-82.
7. Russell ML, Friesen D, Henderson RD, Hanna WM. Ultrastructure of the esophagus in scleroderma. Arthritis Rheum 1982;25: 1117-23.
8. Roberts GP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-controlled study of the pathology of esophageal disease in systemic sclerosis (scleroderma). Gut 2006;55:1697-703.
9. Ibba-Manneschi L, Del Rosso A, Pacini S, Tani A, Bechi P, Matucci-Cerinic M. Ultrastructural study of the muscle coat of the gastric wall in a case of systemic sclerosis. Ann Rheum Dis 2002;61:754-6.
10. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
11. Bombardieri S, Medsger TA Jr, Silman AJ, Valentini G. The assessment of the patient with systemic sclerosis: introduction. Clin Exp Rheumatol 2003;21 Suppl 29:S2-4.
12. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23:691-712.
13. Jaovisidha K, Csuka ME, Almagro UA, Soergel KH. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum 2005; 34:689-702.